Drugs / BRIMOCHOL
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT06948357 | Mar → Sep 2025 overdue | presbyopia | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT04774237 | Mar → Oct 2021 | presbyopia | Visus Therapeutics | Completed | No outcome recorded |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT05270863 | Mar 2022 → Mar 2023 | presbyopia | Visus Therapeutics | Completed | Met primary |
| Phase 3 | NCT05135286 | Mar 2022 → Mar 2025 | presbyopia | Visus Therapeutics | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BRIMOCHOL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05135286 ↗ |
| Known as | BRIMOCHOL PF | “BRIMOCHOL PF eye drops, CARBACHOL PF eye drops, Brimonidine eye drops and Placebo were administered in 7 treatment sequences in various combinations and doses” NCT06948357 ↗ |
| Route | Topical | “BRIMOCHOL™ Topical Ophthalmic Solution” NCT04774237 ↗ |